Hypertension (High Blood Pressure) News and Research

RSS

Hypertension (or high blood pressure) is a condition where the pressure of the blood flowing through the arteries of the body is higher than it should be. Much like the pressure of the air in a tire, if the pressure of the blood is too high it can damage the arteries and organs of the body. Just like the tire, if the pressure suddenly becomes very high, catastrophic events can happen. Similarly, if the pressure remains somewhat elevated for a long enough period of time, premature wear and failure can occur.

Hypertension has its worst effects on the heart, kidneys, eyes, and brain. High blood pressure is a risk factor for heart attack, stroke, kidney failure, hemorrhages of the retina of the eye, and generalized atherosclerosis (hardening of the arteries all over the body).

And the word is! all diets are equal when it comes to weight loss

It has been well documented that obesity-related problems are currently among the most serious health problems facing many of the world's developed nations.

3 Jul 2007

Therapeutic value of meditation unproven

There is an enormous amount of interest in using meditation as a form of therapy to cope with a variety of modern-day health problems, especially hypertension, stress and chronic pain, but the majority of evidence that seems to support this notion is anecdotal, or it comes from poor quality studies, say Maria Ospina and Kenneth Bond, researchers at the University of Alberta/Capital Health Evidence-based Practice Center in Edmonton, Canada.

29 Jun 2007

Lowering cardiac risk later in life

In a study published in the July 2007 issue of The American Journal of Medicine, researchers from the Medical University of South Carolina, Charleston found that people 45 to 64 years of age who added healthy lifestyle behaviors could substantially reduce their risk for cardiovascular disease (CVD) and reduce their death rate.

29 Jun 2007

How medical homes promote equity in health care

Providing minority patients a medical home in which they have a regular doctor or health professional who oversees and coordinates their care would help eliminate racial and ethnic health disparities and promote more health care equity, says a new report from the Commonwealth Fund.

28 Jun 2007

Bayer and Onyx submit supplemental NDA for Nexavar

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.

28 Jun 2007

Pediatric chronic disease poses future health and welfare challenges

The increased incidence of chronic conditions among American children predicts serious strains on health care and social welfare systems in the future, caution investigators from Massachusetts General Hospital (MGH) and Harvard School of Public Health (HSPH).

27 Jun 2007

Hyperglycemia and adverse pregnancy outcome study (HAPO)

Gestational diabetes may place a much higher percentage of pregnant women -- and their unborn babies -- at risk for adverse outcomes than previously believed, according to a major international study presented at the American Diabetes Association's 67th Annual Scientific Sessions.

23 Jun 2007

Morning sickness may indicate lower risk of breast cancer

It may not seem so at the time, but women who suffer through morning sickness during their pregnancies actually may be fortunate.

23 Jun 2007

Ranbaxy receives tentative approval to manufacture Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

23 Jun 2007

Obese heart attack patients more likely to survive after treatment than normal weight patients

Obese and very obese patients have a lower risk of dying after they have been treated for heart attacks than do normal weight patients, according to research published in the European Heart Journal today (Wednesday 20 June).

20 Jun 2007

Medicare Part D plans vary across U.S.

An examination of Medicare Part D plans in California and Hawaii reveals wide variations in drug formularies, but indicates that for many classes of drugs, it is possible to find at least one or more drug that is covered by nearly all Part D plans, according to a study in the June 20 issue of JAMA: The Journal of the American Medical Association

20 Jun 2007

Researchers use 'genomic pathway' to predict Parkinson's

A new Mayo Clinic study provides strong evidence that the joint effects of common DNA variations in several genes that encode proteins within a well-defined biological pathway largely explain why some persons get Parkinson's disease while others don't, and even predict with great accuracy at what age people might develop their first symptoms.

17 Jun 2007

Lupin announces FDA approval of Trandolapril tablets

Lupin Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Trandolapril Tablets, 1mg, 2mg and 4mg. Commercial shipments of Trandolapril tablets have commenced.

17 Jun 2007

New guidelines for management of arterial hypertension

The European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) have released new Guidelines on the management of Arterial Hypertension, which can be found in the European Heart Journal, the official journal of the ESC and Europe's leading cardiology journal.

17 Jun 2007

Solvay Pharmaceuticals submits supplemental NDA for AndroGel

Solvay Pharmaceuticals, Inc., has announced that it submitted a supplemental New Drug Application (sNDA) for AndroGel (testosterone gel) 1% CIII to the U.S. Food and Drug Administration (FDA) for treatment in male adolescents ages 13-17 years old with primary or secondary hypogonadism.

17 Jun 2007

Isradipine may slow Parkinson's

Gloria E. Meredith, Ph.D., collaborated with D. James Surmeier, Ph.D. and other scientists at Northwestern University to study the drug, Isradipine, and its possible effects on Parkinson's disease.

17 Jun 2007

New rheumatoid arthritis genes identified

Researchers at the University of Manchester have identified evidence of several new genes behind the chronic inflammatory disease rheumatoid arthritis (RA), which affects 387,000 people in the UK.

16 Jun 2007

Snake venom medication

A chemist at the Vienna University of Technology (TU Vienna) is looking for unusual structures in snake venom and plans to prove their medical effectiveness.

16 Jun 2007

Link between restless legs syndrome and hypertension

An international team of researchers, led by Emory University clinician scientists, has found evidence that people suffering from moderate to severe cases of restless legs syndrome (RLS) are at significantly increased risk for developing hypertension.

15 Jun 2007

High pulse pressure linked to increased risk for high-tension open-angle glaucoma

Individuals with a high pulse pressure (the difference between the systolic [top number] and diastolic [bottom number] blood pressure), appear to have an increased risk for high-tension open-angle glaucoma, according to a report in the June issue of Archives of Ophthalmology.

14 Jun 2007